Background The pedACR criteria are validated to analyse the response to a treatment but do not indicate the absolute disease activity nor the absolute improvement. This study correlates the JADAS 71 and 10 to the PedACR 30/50/70.
Methods Data of the GERMAN BIKER-registry were used to compare the JADAS71 and -10 (Phy. global VAS 0–10cm, Par./pati. global VAS 0–10cm, Active joint count 0-71, Normalized ESR [ESR-20/10]) to the PedACR criteria.
Results 7960 reports from 1470 JIA pts treated with Etanercept have been analysed. After 3 mths 75% of pts achieved a PedACR30. This number increased to 83% at mth 12 and remained stable thereafter. At mth 3, 45% of pts achieved a PedACR70. This number increased to 62% at mth 12. The median (range) JADAS71 decreased from 18 (0-85) to 4 (0-81) at mth 3, 3 (0-83) at month 6 and 3 (0-57) at month 12, the JADAS10 decreased from 17 (0-40) to 4 (0-35), 3 (0-35), and 3 (0-36). At patient-visits with a PedACR30 the median JADAS10 was 11 (0-29), for PedACR50 6 (0-26), for PedACR70 1 (0-19). In Patient-visit with a failure according to the PedACR the JADAS10 was 12 (0-37). The JADAS71 was 11 (0-49) for PedACR30 responses, 6 (0-47) for PedACR50, 1 (0-25) for PedACR70 response and 12 (0-84) for non-responders (figure). In pts not achieving PedACR30 the JADAS71 and the JADAS10 slightly decreased. In patients achieving a PedACR30/50/70 the JADAS71 decreased by 9.9, 12.3 and 16.7 points, while the JADAS10 decreased by 7.4, 10.0 and 14.9. 1116 (17%) pts achieved the prelim.criteria for inactive disease corresponding to a JADAS-score of 0.
Conclusions The JADAS allows assessing of absolute disease activity and decreased corresponding to the PedACR. The change from baseline for each of the JADAS measures showed adequate ability to classify each of the PedACR accurately.
Disclosure of Interest G. Horneff Grant/Research support from: Abbott, Pfizer, K. Minden Grant/Research support from: Pfizer, I. Foeldvari: None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.